TransCode Therapeutics, Inc.

US$1.49As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RNAZHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (93.21%)
Div yield —
ROE (59.28%)
Biotechnology
Beta (5Y) 1.27
PE TTM —
TSR TTM (86.70%)
Mkt cap US$25.23M
ROIC (21.84%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.77
18.79%
(39.70%)
Hold 11|2|3|0|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.03
0.03
0.03
0.03
8.04%
10.03%
17.38%
9.66%
Revenue$M
1.953
1.978
2.096
2.154
14.00%
14.48%
15.61%
12.84%
Peers (US$25.23M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.857
(0.182)
(0.187)
EBIT/Intx
0.898
0.516
0.424
Own earn%
(64.87)
(53.20)
(48.47)
Sh yield%
49.83
38.62
34.00
Owners
Insiders/Inst%
10.04
45.63
Short interest%
3.60
SBC / revenue%
3.53
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
20–24
$1 testx
0.1
Incr. ROIC%
23